StockNews.com Initiates Coverage on Affimed (NASDAQ:AFMD)

Stock analysts at StockNews.com initiated coverage on shares of Affimed (NASDAQ:AFMD) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on AFMD. Wells Fargo & Company decreased their target price on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Affimed in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $13.50.

Affimed Stock Up 0.3 %

Affimed stock opened at $0.71 on Tuesday. Affimed has a 12-month low of $0.69 and a 12-month high of $8.95. The firm has a 50 day moving average of $0.96 and a 200 day moving average of $2.03. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93.

Institutional Investors Weigh In On Affimed

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in shares of Affimed during the third quarter worth $44,000. Point72 Asset Management L.P. grew its stake in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 15,108 shares in the last quarter. Intellectus Partners LLC increased its position in shares of Affimed by 34.0% during the fourth quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 32,053 shares during the period. Northern Trust Corp bought a new stake in Affimed during the 4th quarter valued at $218,000. Finally, FMR LLC lifted its stake in Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the period. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.